Abstract
Neuropeptide Y (NPY) has neuromodulatory actions on multiple brain functions including endocrine, behavioral, and circadian processes. Behavioral studies suggest that NPY is a potent anxiolytic; however, little is known about how NPY affects general arousal and/or attention states. The present study evaluated the effects of NPY on spontaneous brain activity as well as auditory processing by using electrophysiological measures. Electroencephalographic (EEG) and event-related potentials (ERPs) were obtained in awake animals after intracerebroventricular administration of NPY (1.0, 3.0 nmol) and two of its analogs, active at Y1 (1.0, 3.0 nmol) and Y2 (1.0, 3.0 nmol) receptor sites. NPY was found to produce dose-related effects on electrophysiological measures. Spectral analyses of the EEG revealed that NPY produced slowing of delta activity (1–2 Hz) in the frontal cortex and high frequency theta activities (6–8 Hz) concomitant with a speeding up of low frequency theta (4–6 Hz) in cortex, hippocampus, and amygdala. At higher doses (3.0 nmols) in addition to shifts in frequency, EEG power was also significantly reduced in all frequencies (0.5–50 Hz) in cortex, and in the higher frequencies (8–32 Hz) in the amygdala. The Y1 and Y2 agonists had a somewhat different profile of EEG effects than the parent compound. At the 1 nmol dose both agonists were found to produce selective depressions in power in the hippocampus. The 3.0 nmols dose of the Y1 agonist produced decreases in EEG stability, an effect commonly produced by anxiolytic drugs, whereas the Y2 agonist produced increases in EEG stability in cortex and amygdala. Auditory processing, as assessed by ERPs, was affected most significantly in the frontal cortex where dose-dependent decreases in the N1 component of the ERP, a finding also commonly seen after anxiolytics, was found. Y1 and Y2 agonists were also found to significantly reduce the amplitude of the N1 component of the ERP but less so than the parent compound. The electrophysiological and behavioral profiles of NPY and the Y1 agonist resembles those of anxiolytics such as ethanol and benzodiazepines. Taken together these data suggest that electrophysiological measures of the actions of this peptide system may represent a new potentially useful assay for the development of anxiolytic drugs.
Similar content being viewed by others
Article PDF
References
Abe M, Saito M, Shiumazu T (1989); Neuropeptide Y and norepinephrine injected into the paraventricular nucleus of the hypothalamus activate endocrine pancreas. Biomed Res 10:431–436
Adrian TE, Allen JM, Bloom SR, Ghatei MA, Rossen MN, Roberts GW, Crow TJ, Tatemoto K, Polak, JM (1983): Neuropeptide Y distribution in human brain. Nature 306(5943):584–586
Albers HE, Ferris CF (1984): Neuropeptide Y: Role in lightdark cycle entrainment of hamster circadian rhythms. Neurosci Lett 50(1–3):163–168
Allen YS, Adrian TE, Allen JM, Tatamoto K, Crow TJ, Bloom SR, Polak JM (1983): Neuropeptide Y distribution in the rat brain. Science 221(4613):877–879
Aoki C, Pickel VM (1989): Neuropeptide Y in the cerebral cortex and the caudate-putamen nuclei: Ultrastructural basis for interactions with GAAGAergic and non-GABAergic neurons. J Neurosci 9(12):4333–4354
Aoki C, Pickel VM (1990): Neuropeptide Y in cortex and striatum: Ultrastructural distribution and coexistence with classical neurotransmitters and neuropeptides. Ann NY Acad Sci 611:185–205
Bard JA, Walker MW, Branchek TA, Weinshank RL (1995): Cloning and functional expression of a human Y4 subtype receptor for pancreatic polypeptide, neuropeptide Y and peptide YY. J Biol Chem 270(45):26762–26765
Borbely AA (1992): Effects of hypnotics on sleep regulation and the sleep EEG. Clin Neuropharmacol 15(Suppl 1 Pt A):359A
Catzeflis C, Pierroz DD, Rohner-Jeanrenuad F, Rivier JE, Sizonenko PC, Aubert ML (1993): Neuropeptide Y administered chronically into the lateral ventricle profoundly inhibits both the gonadotropic and the somatotropic axis in intact adult female rats. Endocrinology 132(1):224–234
Chronwall BM, DiMaggio DA, Massari VJ, Pickel VM, Ruggiero DA, O'Donohue TL (1985): The anatomy of neuropeptide-Y-containing neurons in rat brain. Neuroscience 15(4):1159–1181
Clark JT, Kalra PS, Crowley WR, Kalra SP (1984): Neuropeptide Y and human pancreatic polypeptide stimulate feeding behavior in rats. Endocrinology 115(1):427–429
Danger JM, Tonon MC, Jenks BG, Saint-Pierre S, Martel JC, Fasolo A, Breton B, Quirion R, Pelletier G, Vaudry H (1990): Neuropeptide Y: Localization in the central nervous system and neuroendocrine functions. Fundam Clin Pharmacol 4:307–340
de Quidt ME, Emson PC (1986a): Distribution of neuropeptide Y-like immunoreactivity in the rat central nervous system. I. Radioimmunoassay and chromatographic characterization. Neuroscience 18(3):527–543
de Quidt ME, Emson PC (1986b): Distribution of neuropeptide Y-like immunoreactivity in the rat central nervous system. II. Immunohistochemical analysis. Neuroscience 18(3):545–618
Donchin E, Coles MGH (1988): Is the P300 component a manifestation of context updating? Behav Brain Sci 11:357–374
Dumont Y, Fournier A, St-Pierre S, Schwartz TW, Quirion R (1990): Differential distribution of neuropeptide Y1 and Y2 receptors in the rat brain. Eur J Pharmacol 191(3):501–503
Ehlers CL (1984): Role of selected neuropeptides in the development of epileptiform discharges. In Fariello RG, Morselli PL, Lloyd KG, Quesney LF, Engel J Jr (eds), Neurotransmitters, Seizures, and Epilepsy II. New York, Raven Press, pp 295–304
Ehlers CL (1988): ERP responses to ethanol and diazepam administration in squirrel monkeys. Alcohol 5:315–320
Ehlers CL (1989): EEG and ERP responses to naloxone and ethanol in monkeys. Prog Neuropsychopharmacol Biol Psychiatry 13:217–228
Ehlers CL, Havstad JW (1982): Characterization of drug effects on the EEG power spectral band time series analysis. Psychopharmacol Bull 18:43–47
Ehlers CL, Henriksen SJ, Wang M, Rivier J, Vale W, Bloom FE (1983): Corticotropin releasing factor produces increases in brain excitability and convulsive seizures in rats. Brain Res 278:332–336
Ehlers CL, Kaneko WM, Robledo P, Lopez A (1994): Long latency event-related potentials in rats: Effects of task and stimulus parameters. Neuroscience 62(3):759–769
Ehlers CL, Reed TK (1987): Ethanol effects on EEG spectra in monkeys: Comparison to morphine and diazepam. Electroencephalogr Clin Neurophysiol 66:317–321
Ehlers CL, Reed TK, Wang M, Lebrun CJ, Koob GF (1985): EEG effects of subcutaneous and intracerebroventricular injections of arginine vasopressin in the rat. Psychopharmacology 87:430–433
Ehlers CL, Reed TK, Henriksen SJ (1986): Effects of corticotropin-releasing factor and growth hormone-releasing factor on sleep and activity in rats. Neuroendocrinology 42:467–474
Ehlers CL, Wall TL, Chaplin RI (1991): Long latency event related potentials in rats: Effects of dopaminergic and serotonergic depletions. Pharamcol Biochem Behav 38:789–793
Ehlers CL, Chaplin RI (1992): Long Latency event-related potentials in rats: The effects of changes in stimulus parameters and neurochemical lesions. J Neural Transm 88:61–75
Ehlers C, Kaneko WM, Wall TL, Chaplin RI (1992): Effects of dizocilpine (MK-801) and ethanol on the EEG and event-related potentials (ERPs) in rats. Neuropharm 31(4):369–378
Ehlers CL, Wall TL, Schuckit MA (1989): EEG spectral characteristics following ethanol administration in young men. EEG Clin Neurophysiol 73:179–187
Fuxe K, Agnati LF, Härfstrand A, Zini I, Tatemoto K, Pich EM, Hökfelt T, Mutt V, Terenius L (1983): Central administration of neuropeptide Y induces hypotension bradypnea and EEG synchronization in the rat. Acta Physiol Scan 118:189–192
Fuxe K, Agnati LF, Härfstrand A, Eneroth P, Cintra A, Tinner B, Pich EM, Aronsson M, Bunnemann B, Lang R, Ganten D (1989): Studies on the neurochemical mechanisms underlying the neuroendocrine actions of neuropeptide Y. In Mutt V, Hokfelt T, Fuxe K, Lundberg JM (eds), Neuropeptide Y. New York, Raven Press, pp 115–136
Gehlert DR (1994): Subtypes of receptors for neuropeptide Y: Implications for the targeting of therapeutics. Life Sci 55:551–562
Gehrmann JE, Killam JF Jr (1978): Studies of central functional equivalence—Time varying distributions of power in discrete frequency bands of the EEG as a function of drug exposure. Neuropharmacology 17:747–759
Gerald C, Walker MW, Vaysse PJ, He C, Branchek TA, Weinshank RL (1995): Expression cloning and pharmacological characterization of a human hippocampal neuropeptide Y/peptide YY Y2 receptor subtype. J Biol Chem 270(45):26758–26761
Gerald C, Walker MW, Criscione L, Gustafson EL, Batzl-Hartmann C, Smith KE, Vaysse P, Durkin MM, Laz TM, Linemeyer DL, Schaffhauser AO, Whitebread S, Hofbauer KG, Taber RI, Branchek TA, Weinshank RL (1996): A receptor subtype involved in neuropeptide-Y-induced food intake. Nature 382(6587):168–171
Gray TS, Morley JE (1986): Neuropeptide Y: Anatomical distribution and possible function in mammalian nervous system. Life Sci 38:389–401
Grillon C, Ameli R (1994): P300 assessment of anxiety effects of processing novel stimuli. Int J Psychophysiol 17(3):205–217
Grundemar L, Sheikh SP, Wahlestedt C (1993): Characterization of receptor types for neuropeptide Y and related peptides. In Colmers WF, Wahlestedt C (eds), The Biology of Neuropeptide Y and Related Peptides. Totawa, NJ, Humana Press, p 197
Gusstafson EL, Card JP, Moore RY (1986): Neuropeptide Y localization in the rat amygdaloid complex. J Comp Neurol 251(3):349–362
Heilig M (1995): Antisense inhibition of neuropeptide Y (NPY)-Y1 receptor expression blocks the anxiolytic-like action of NPY in amygdala and paradoxically increases feeding. Regul Pept 59(2):201–205
Heilig M, Koob GF, Ekman R, Britton KT (1994): Corticotropin-releasing factor and neuropeptide Y: Role in emotional integration TINS 17(2):80–85
Heilig M, McLeod S, Brot M, Heinricks SC, Menzaghi F, Koob GF, Britton KT (1993): Anxiolytic-like action of neuropeptide Y: Mediation by Y1 receptors in amygdala, and dissociation from food intake effects. Neuropsychopharmacology 8(4):357–363
Heilig M, McLeod S, Koob GF, Britton KT (1992): Anziolyticlike effect of neuropeptide Y (NPY), but not other peptides in an operant conflict test. Regul Pept 41(1):61–69
Heilig M, Söderpalm B, Engel JA, Widerlöv E (1989): Centrally administered neuropeptide Y (NPY) produces anxiolytic-like effects in animal anxiety models. Psychopharmacology 98(4):524–529
Heilig M, Widerlöv E (1990): Neuropeptide Y: An overview of central distribution, functional aspect, and possible involvement in neuropsychiatric illnesses. Acta Psychiatr Scan 82:95–114
Heilig M, Widerlöv E (1995): Neurobiology and clinical aspects of Neuropeptide Y. In Nemeroff CB, De Souse EB (eds), Critical Reviews in Neurobiology. 9(2–3):115–136
Hendry JHC (1993): Organization of neuropeptide Y neurons in the mammalian central nervous system. In Colmers WF, Wahlestedt C (eds), The Biology of Neuropeptide Y and Related Peptides. Totowa, NJ, Humana Press, p 65
Hillyard SA, Kutas M (1983): Electrophysiology of cognitive processing. Annu Rev Psychol 34:33–61
Kalra SP, Crowley WR (1992): Neuropeptide Y: A novel neuroendocrine peptide in the control of pituitary hormone secretion, and its relation to lutenizing hormone. Front Neuroendocrinol 13:1–46
Kirby DA, Koerber SC, Craig AG, Feinstein RD, Delmas L, Brown MR, Rivier JE (1993): Defining structural requirements for neuropeptide Y receptors using truncated and conformationally restricted analogues. J Med Chem 36:385–393
Kowall NW, Ferrante RJ, Beal MF et al. (1987): Neuropeptide Y, somatostatin, and reduced nicotinamide adenine dinucleotide phosphate diaphorase in the human striatum: A combined immunocytochemical and enzyme histochemical study. Neuroscience 20(3):817–828
Levine AS, Morley JE (1984): Neuropeptide Y: A potent inducer of consummatory behavior in rats. Peptides 5(6):1025–1029
Leibowitz SF (1988): Hypothalamic paraventricular nucleus: Interaction between alpha 2-noradrenergic system and circulating hormones and nutrients in relation to energy balance. Neurosci Biobehav Rev 12:101–109
Leibowitz SF (1991): A brain neuropeptide Y: An integrator of endocrine, metabolic and behavioral processes. Brain Res Bull 27:333–337
Michel MC (1991): Receptors for neuropeptide Y: Multiple subtypes and multiple second messengers. Trends Pharmacol Sci 12(10):389–394
Moore RY, Card JP (1985): Visual pathways and the entrainment of circadian rhythms. Ann NY Acad Sci 453:123–133
Morley JE, Hernandez EN, Flood JF (1987): Neuropeptide Y increases food intake in mice. Am J Physiol 253(3 Pt. 2):R516–522
Mutt V, Hökfelt T, Fuxe K, Lundgerg JM (eds) (1989): Neuropeptide Y. Karlinska Institute Nobel Conference Series. New York, Raven Press
Nakagawa Y, Shiosaka S, Emson PC, Tohyama M (1985): Distribution of neuropeptide Y in the forebrain and diencephalon: An immunohistochemical analysis. Brain Res 361(1–2):52–60
Parrott RF, Heavens RP, Baldwin BA (1986): Stimulation of feeding in the satiated pig by intracerebroventricular injection of neuropeptide Y. Physiol Behav 36(3):523–525
Pellegrino LJ, Pellegrino AS, Cushman AJ (1979): A Stereotaxic Atlas of the Rat Brain. New York, Plenum Press
Polich J, Fisher A, Starr A (1983): A programmable multitone generator. Behav Res Methods Instrum 15:39–41
Polich J (1987): Comparison of P300 from a passive tone sequence paradigm and an active discrimination task. Psychophysiology 24:41–46
Robledo P, Kaneko WM, Ehlers CL (1995): Effects of neurotensin on EEG and event-related potentials in the rat. Psychopharmacology 118:410–418
Robledo P, Lumeng L, Li T-K, Ehlers CL (1984): Effects of MK 801 and diazepam on the EEG of P and NP rats. Alcohol Clin Exp Res 18(2):363–368
Roth WT (1973): Auditory evoked responses to unpredictable stimuli. Psychophysiology 10:125–137
Sawchenko PE, Swanson LW, Grzanna R, Howe PR, Bloom SR, Polak JM (1985): Colocalization of neuropeptide Y immunoreactivity in brainstem catecholaminergic neurons that project to the paraventricular nucleus of the hypothalamus. J Comp Neurol 241(2):138–153
Shen CL (1987): Distribution of neuropeptide Y immunoreactivity in the forebrain of the rat. Proc Natl Sci Counc Repub China Part B 11(2):115–127
Squires NK, Squires KC, Hillyard SA (1975): Two varieties long-latency positive waves evoked by unpredictable auditory stimuli in man. Electroencephalogr Clin Neurophysiol 38:387–401
Stanley BG, Daniel DR, Chin AS, Leibowitz SF (1985): Paraventricular nucleus injections of peptide YY and neuropeptide Y preferentially enhance carbohydrate ingestion. Peptides 6(6):521–524
Stanley BG, Leibowitz SF (1984): Neuropeptide Y: Stimulation of feeding and drinking by injection into the paraventricular nucleus. Life Sci 34(26):2635–2642
Tatemoto K, Carlquist M, Mutt V (1982): Neuropeptide Y a novel brain peptide with structured similarities to peptide YY and pancreatic polypeptide. Nature 296(5858):659–660
Verleger R (1988): Event-related potentials and cognition: A critique of the context updating hypothesis and an alternative interpretation of P3. Behav Brain Sci 11:343–356
Wahlestedt C, Ekman R, Widerlöv E (1989): Neuropeptide Y (NPY) in the central nervous system: Distribution, effects and possible relationship to neurological and psychiatric disorders. Prog Neuropsychopharmacol Biol Psychiatry 13(1–2):31–54
Wahlestedt C, Grundemar L, Kakanson R, Heilig M, Shen GH, Zikowsak-Grojec Z, Reis DJ (1990): Neuropeptide Y receptor subtypes, Y1 and Y2. Ann NY Acad Sci 611:7–26
Wahlestedt C, Pich EM, Koob GF, Yee F, Heilig M (1993): Modulation of anxiety and neuropeptide Y-Y1 receptors by antisense oligodeoxynucleotides. Science 259(5094):528–531
Wahlestedt C, Reis DJ (1993): Neuropeptide Y-related peptides and their receptors—are the receptors potential therapeutic drug targets. Annu Rev Pharmacol Toxicol 33:309–352
Wahlestedt C, Skagerberg G, Edman R, Heilig M, Sundler F, Hakanson R (1987): Neuropeptide Y (NPY) in the area of the paraventricular nucleus activates the pituitaryadrenocortical axis in the rat. Brain Res 417:33–38
Wahlestedt C, Yanaihara N, Hakanson R (1986): Evidence for different pre- and postjunctional receptors for neuropeptide Y and related peptides. Regul Pept 13(3–4):307–318
Weinberg DH, Sirinathsinghji DJ, Tan CP, Shiao LL, Morin N, Rigby MR, Heavens RH, Rapoport DR, Bayne ML, Cascieri MA, Strader CD, Linemeyer DL, MacNeil DJ (1996): Cloning and expression of a novel neuropeptide Y receptor. J Biol Chem 271(28): 16435–16438
Wettstein JG, Earley B, Junien JL (1995): Central nervous system pharmacology of neuropeptide Y. Pharmacol Ther 65(3):397–414
Acknowledgements
The authors thank Susan Lopez for help in analyzing the ERPs and EEGs and Erica Bisson and David Cloutier for help in statistical analyses. This work was supported by grants R01 AA06059 and AA00223 to C. L. Ehlers and HL-41910 to J. Rivier.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Ehlers, C., Somes, C., Lopez, A. et al. Electrophysiological Actions of Neuropeptide Y and Its Analogs: New Measures for Anxiolytic Therapy?. Neuropsychopharmacol 17, 34–43 (1997). https://doi.org/10.1016/S0893-133X(97)00001-8
Received:
Revised:
Accepted:
Issue Date:
DOI: https://doi.org/10.1016/S0893-133X(97)00001-8
Keywords
This article is cited by
-
Plasma neuropeptide Y levels in Chinese patients with primary insomnia
Sleep and Breathing (2015)